The ShikiFactory100 project will generate results in a range of formats. Navigate this page to find project deliverables, scientific publications and available communication material.
Public deliverables will be made available below as soon as they are complete:
WP1: Project Management - led by SilicoLife
WP2: Retrosynthesis & Enumeration - led by SilicoLife
WP3: Chemical Synthesis of New Products - led by GalChimia
WP4: Gene Discovery & Protein Engineering - led by Universidade NOVA de Lisboa
WP5: In Silico Metabolic Engineering - led by EMBL
WP6: Pathway Screening - led by University of Manchester
WP7: Cell Factory Construction - led by DTU
WP8: Product Validation & Sustainability Appraisal - led by DSM
WP9: Exploitation and Dissemination - led by NNFCC
Below is a collection of resources used to promote and disseminate information associated with the ShikiFactory100 project.
Project Leaflet - contains general information about the project and describes its three major vectors (discovery, design & implementation, and validation).
Roll-up Banner - for project promotion at events such as conferences and trade fairs.
The Shikimate Pathway - this article aims to provide background information about the research carried out by the project. It describes key metabolic pathways for living organisms, including the shikimate pathway, central to the Shikifactory100 project, and their applications at an industrial level.
Synthetic Biology for the Production of Biobased Molecules - this article aims to provide a background to the field of synthetic biology.
Psylocibin is a compound most
famously found in “magic mushrooms”. It has potent psychotropic properties,
which aside from its notorious recreational uses, is also thought to hold
potential for the treatment of a range of psychological and neurological ailments.
In their study, Milne et al demonstrate that psylocibin could be
produced from an engineered strain of the well-known yeast Saccharomyces
cerevisiae. Furthermore, the yeast could produce psilocybin derivatives
that may have new useful pharmaceutical properties.
Aromatic amino acids are valuable
chemicals and are precursors for a range of industrial compounds. This
particular study looks at the widely used p-coumaric acid and aims to
improve its production in yeast. Borja et al observed a significant
effect that the carbon source had on the production, where xylose was a better
substrate for p-coumaric acid
production than glucose.
Rosmarinic acid is a compound found in several plants. It is widely used as a food and cosmetic ingredient and has various pharmaceutical applications. However the production of this compound remains limited as natural availability is low and chemical synthesis is too complex. This study, for the first time, shows recombinant production of rosmarinic acid in engineered yeast.
Resveratrol is a plant secondary
metabolite with a range of medicinal properties. Its low availability from the
direct plant source has led researchers to develop microbial production of the
compound, however commercially viable production levels are still proving
difficult. In this study, the authors are demonstrating that the use of the
yeast Yarrowia lipolytica as host organism is a promising host for the
production of resveratrol along with several other valuable products.
Metabolic engineering involves the
engineering and optimization of processes from single-cell to fermentation in
order to increase production of valuable chemicals. Significant advances in
strain engineering are leading metabolic engineering to become a truly manufacturing
technology capable of producing goods on an industrial scale. This review
article demonstrates that the success of metabolic engineering heavily relies
on biodesign algorithms which identify promising production routes and
The increasing demand for bio-based
compounds is now allowing biofoundries to produce and deliver valuable goods on
an industrial scale. Nowadays, entire portfolios of producer strains are being
developed in record times thanks to the integration and automation of the
design, build, test and learn (DBTL) steps of the production cycle. As new in
silico design tools are being developed to improve the efficacy of DBTL pipelines, the
ever-increasing data gathered by biofoundries can now be added to these in-silico tools,
therefore rendering them even more powerful and reliable. This paper discusses
the future of biomanufacturing in an environment where the process will not
only be fully automated, but will also be able to learn and adapt quickly to
produce optimal designs.
Scientific results from the ShikiFactory100 project will also be made available via CORDIS (Community Research and Development Information Service, the European Commission's public repository for the dissemination of information from all EU-funded research projects.
Results are to be stored and shared between partners via the ICE and GitLab platforms.